Skip to Content

What is the difference between Truxima and Rituxan?

Both Truxima and Rituxan contain rituximab. Are they used to treat the same conditions?

Medically reviewed by Drugs.com Last updated on Sep 30, 2019.

Official Answer

by Drugs.com

Truxima (rituximab-abbs) is a biosimilar to Rituxan (rituximab). Truxima is indicated for the treatment of non-Hodgkin’s lymphoma, while Rituxan is indicated for the expanded treatment of non-Hodgkin’s lymphoma, plus several other medical conditions.

Biosimilars are highly similar to an already-approved biological product with no known differences in safety and effectiveness. The FDA-approved indications and usages differ between Rituxan and Truxima.

Truxima and Rituxan belong to the class of drugs called CD20-directed cytolytic antibodies

Truxima is approved for the treatment of adult patients with non-Hodgkin’s lymphoma (NHL):

  • Non-Hodgkin’s Lymphoma (NHL):
    • Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent.
    • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.
    • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.

Rituxan is indicated for the expanded treatment of non-Hodgkin’s lymphoma, plus several other medical conditions in adults patients, including:

  • Non-Hodgkin’s Lymphoma (NHL):
    • Relapsed or refractory, low grade or follicular, CD20-positive B cell NHL as a single agent.
    • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy.
    • Non-progressing (including stable disease), low-grade, CD20- positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.
    • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.
  • Chronic Lymphocytic Leukemia (CLL):
    • Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
  • Rheumatoid Arthritis (RA):
    • In combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies.
  • Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)
    • in combination with glucocorticoids inpatients two years of age and older.
  • Pemphigus Vulgaris (PV):
    • Moderate to severe disease in adult patients.

For more information, see What Are Biosimilars? Top Facts You May Not Know

Related Medical Questions

Drug Information

Related Support Groups

Hide